

# Correction: Integrum launches patient-facing website in the US to increase patient flow and awareness of OPRA Implant System

Updated hyperlink to website

**Möln dal, Sweden, May 5, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) launches today a patient-facing website in the US. The website has been developed to better support amputees and their families ahead of choosing a prosthetic system, while also enabling Integrum to better track and direct patients to the right care unit. The website is also being prepared for launch in additional countries.**

Integrum works strategically and systematically to ensure that more patients worldwide gain access to the company's innovative, bone-anchored implant system OPRA Implant System. The establishment is currently concentrated in the US, Europe, and Ukraine, where a number of Centers of Excellence have been built – clinics with surgeons who possess the specialist expertise required for implanting the prosthetic system.

Although the infrastructure is now in place to perform many operations, it remains a challenge to reach all the amputees who would benefit from replacing their socket prostheses with bone-anchored prostheses from Integrum. To better reach and support these individuals, Integrum has developed a patient-facing, easy to navigate website. On the website, amputees and their families can find comprehensive information about OPRA Implant System and be directed to care units that can take the process forward. The website is also connected to Integrum's internal systems, enabling the company to more efficiently track the flow of potential new users of OPRA Implant System.

"This patient-facing website is critical for us to accelerate the commercialization of OPRA Implant System. Today, we rely too heavily on healthcare providers independently identifying amputees who are unhappy with their socket prostheses and letting them know that alternatives exist. But we are confident that there are significantly more people out there who will consider switching to bone-anchored implants once they understand the benefits – and that we can do a better job of reaching them. At the same time, this is a big decision for the individual, and we need to approach that with respect, providing plenty of information and support throughout the entire process. We are now able to do this in a whole new way, and I look forward to seeing the US organization's new approach in action – and then rolling this website out to more markets," comments Martin Hillsten, CEO of Integrum.

[The new website can be found at opraimplantsystem.com](https://opraimplantsystem.com)

Read an extended comment from CEO Martin Hillsten and an interview with project manager Johan Pfannenstill at Integrum Investor News: [investors.integrum.se](https://investors.integrum.se)

**For more information, please contact:**

Martin Hillsten, CEO

Tel: +46 733 55 28 32

Email: [martin.hillsten@integrum.se](mailto:martin.hillsten@integrum.se)

**About Us**

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.